



*FOR IMMEDIATE RELEASE*

**CEDRUS INVESTMENTS SIGNED COOPERATION AGREEMENT WITH  
SINOPHARM NUTRACEUTICALS INDUSTRIAL (SHANGHAI)  
ON 16<sup>TH</sup> NOVEMBER 2018**

SHANGHAI, 21<sup>st</sup> November 2018 – **Cedrus Investments** (“Cedrus”), a global boutique investment firm, signed a cooperation agreement with Sinopharm Nutraceuticals Industrial (Shanghai) (“Sinopharm Nutraceuticals”) on 16<sup>th</sup> November 2018 in Shanghai for the exploration and execution of **investment opportunities in the pharmaceutical, healthcare and biotechnology industries** by leveraging each other’s strengths and resources.

Under this agreement, Cedrus brings access to proprietary deal flow from around the globe, deep technical expertise in the biopharmaceutical industry, diverse international business experience, and the capability to structuring and executing transactions – acquisitions and licensing-rights deals.

Due to our relationships, expertise and network in the life sciences industry, Cedrus has access to companies with cutting-edge technologies worldwide, including those in Europe, Australia and North America. Cedrus through its acquisitions of some China intellectual property rights, will **jointly develop these overseas ingenious technologies with Sinopharm Nutraceuticals**, aiming to bring the **innovative technologies** selected by Cedrus and Sinopharm Nutraceuticals to the Chinese market to **address the medical needs for patients in China**.

Sinopharm Nutraceuticals is an independent member of the Sinopharm Group, which is also one of its minority shareholders. The firm invests in new technologies and new medical care business models. For overseas investments, the firm aims to invest in new healthcare technologies and bring them to China. Under this agreement, Sinopharm Nutraceuticals brings **valuable on the ground experience**, including **strong capabilities in integrating a variety of resources, including sales and distribution to hospitals**.

Both companies are committed to helping build the life sciences industry in China by introducing **innovative therapies and technologies** that meet the significant unmet needs of the Chinese population in a **cost-effective and efficient manner**.



CEDRUS INVESTMENTS

赛 德 思 投 资

**Mr. Pu Qiang**, Chairman of Sinopharm Nutraceuticals said, “I am delighted to have this collaboration with Cedrus, together we aim to bring overseas novel technologies to China which will be beneficial to the country and its people, as well as introducing Chinese ingenious technologies to rest of the world.”

Cedrus’ Chairman **Mr. Rani Jarkas** said, “I am excited to establish a long-term relationship with Sinopharm Nutraceuticals. This collaboration demonstrates Cedrus’ continued commitment to contributing to the growth of the life sciences industry in China and a leading player in innovative technology investments. I look forward to working closely with Sinopharm Nutraceuticals going forward and contributing positively to the Chinese healthcare industry.”

---

#### **About Cedrus Investments**

[Cedrus Investments](#) is a global boutique investment firm that offers expertise in [private wealth management](#), [asset management](#) and [financial advisory services](#) to a clientele of leading institutional investors, corporations, family offices and high net worth individuals around the world.

SOURCE Cedrus Investments

For further information about Cedrus Investments, please visit [www.cedrusinvestments.com](http://www.cedrusinvestments.com).

Media Enquiry:

Cedrus Investments Ltd.

Amy Sin

+852-3519-2828

[information@cedrusinvestments.com](mailto:information@cedrusinvestments.com)